Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

Inclusion criteria

• Healthy adult volunteers aged 19 ≤ ~ < 55-year-old.
• Weight ≥55kg (man) or 45kg (woman), with calculated body mass index (BMI) of 17.5 ≤ ~ < 30.5 kg/m2.
• Those who have no congenital diseases or chronic diseases within 3 years and have no abnormal symptoms or findings.
• Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and 12-lead ECG results at screening.
• Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.
• Those who agree to contraception until the 1 month after last administration of clinical trial drugs.
• Those who have the ability and willingness to participate during the entire clinical trail.

Exclusion criteria

• Those who have clinically significant disease or medical history of heart failure, Hepatopathy, Type 1 Diabetes, Diabetic ketoacidosis, Edema, Renal dysfunction, galactose intolerance, glucose-galactose malabsorption. And Those who receive intravenous administration of radioactive iodine contrast agents (for intravenous urography, venous cholangiography, angiography, computed tomography using contrast agents, etc.) during clinical trial.
• Those who have past medical history of gastrointestinal disorder (Crohn's disease, ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect the absorption of investigational drug.
• Those who have the test results written below

• AST, ALT > 2 times higher than upper normal level
• Those who exceeding an alcohol consumption criteria(210g/week) within 6 months before the first administration of investigational drug.

• Beer 1 glass(250ml, Alcohol contents 5%) = 10g
• Soju 1 glass(50ml, Alcohol contents 20%) = 8g
• Wine 1 glass(125ml, Alcohol contents 12%) = 12g
• Those who exceeding smoking criteria(20 cigarettes/day) within 6 months before the first administration of investigational drug.
• Those who received investigational durg by participating in other clinical trial within 6 months before the first administration of investigational drug.
• Those who have vital sign written below

• systolic blood pressure ≥140 mmHg or < 90 mmHg
• diastolic blood pressure ≥ 90 mmHg or < 60 mmHg
• Those who have a drug or alcohol abuse history within 1 year before the first administration of investigational drug.
• Those who take barbiturate and related (causing induction or inhibition. of metabolism) drug within 30 days before the first administration of investigational drug.
• Those who received Ethical-the-counter (ETC) drugs or Over-the-counter (OTC) drugs within 10 days before the first administration of investigational drug.
• Those who donated whole blood within 2 months or apheresis within 1 month before the first administration of investigational drug.
• Those who severe acute/chronic medical or mental condition which can increase the safety risk by administration of investigational drug.
• Those who have history of hypersensitivity to active pharmaceutical ingredient or additives.
• Those who are pregnant or breastfeeding.
• Those who can't ingest a high fat diet.
• Those who are deemed inappropriate to participate in clinical trial by investigators.